About the Program

The African Vaccine Acquisition Trust of 7th Floor, Happy World House, 37 Sir William Newton Street, Port-Louis 11328, Mauritius, a centralised negotiating, purchasing, and payment agent incorporated on behalf of the AU Member States and CARICOM Member States for the purchase of COVID-19 vaccines pursuant to the AVAT Framework.

The AVAT No Fault Compensation Scheme, as detailed in the Protocol and its Schedules.

Any AU Member State or CARICOM State that has elected to participate in the AVAT No Fault Compensation Scheme and “Participating Member States” shall mean all such states that have elected to participate in the AVAT No Fault Compensation Scheme.

A serious untoward medical occurrence that (i) is sustained or suffered by a Patient following the administration of a Vaccine, and (ii) results in an Injury, as defined in the Program's Protocol.

A significant deviation, loss, or loss of use of any body structure or body function in an individual with a health condition, disorder, or disease.

The evaluation of an Impairment as provided in the Program's Protocol will be based upon the most recently published edition of the American Medical Association’s Guides to the Evaluation of Permanent Impairment (AMA’s Guides). Impairment percentages or ratings contained in the AMA’s Guides have been developed by medical specialists and are consensus-derived estimates that reflect the severity of the medical condition and the degree to which the Impairment decreases an individual’s ability to perform common activities of daily living.

The Impairment rating is a percentage that represents the extent of a whole person impairment of an individual, based on the organ or body function affected by an Injury (as defined in the Program's Protocol).

A mechanism structured by AVATT in collaboration with the African Export-Import Bank to establish a pan-African centralized procurement platform to ensure Africa’s access to COVID-19 vaccines by creating AVAT and providing assurance for the payment to identified vaccine manufacturers.

A COVID-19 vaccine received in any Participating Member State through the AVAT Framework that:

1. either (A) has licensure or authorization from a stringent (“functional”) regulatory authority or (B) has received WHO prequalification, following licensure or authorization from a stringent (“functional”) regulatory authority, or (C) has been issued authorization for emergency use based on licensure or authorization by a stringent (“functional”) regulatory authority; and
2. is included in Schedule 1 to the Program's Protocol, as updated from time to time; and
3. has received all required approvals and authorizations for importation, distribution, and use in the relevant Participating Member State; and
4. has not reached its Scope of Coverage Endpoint.

A written claim for compensation completed by an Applicant on the application form approved by and provided by the Administrator, as set forth in Schedule 2 to the Program's Protocol, which must be accompanied by all Supporting Evidence, using the prescribed form in Schedule 3 to the Program’s Protocol.

ESIS, Inc., the claims Administrator appointed to manage and administer the Program, including, but not limited to, the receipt and registration of Applications, distributing acknowledgements of receipt of Applications, setting financial reserves for Receivable Claims, review of Applications, Supporting Evidence, and other documents to assess receivability, assessing Receivable Claims, and approve or deny, as the case may be, Payment for compensation, in accordance with the terms of the Program's Protocol.

for each Vaccine, the date which is 24 months following the date on which a Vaccine was first put into circulation by the relevant Vaccine manufacturer within  the AVAT Framework following regulatory approval or an emergency use authorization of such Vaccine by any regulator.

On a per Vaccine basis, the period during which an Applicant may file an Application for compensation under the Program in respect of such Vaccine. The maximum Reporting Period for each Vaccine extends from:

1. the date on which such Vaccine was first put into circulation by the manufacturer within the AVAT Framework, following regulatory approval or an emergency use authorization of such Vaccine by any regulator (as indicated in Schedule 1 to the Program's Protocol); and
2. terminates on the date which is 36 calendar months immediately after the Scope of Coverage Endpoint for such Vaccine (as indicated in Schedule 1 to the Program's Protocol), provided always that the Vaccine was administered before this Vaccine’s Scope of Coverage Endpoint (as defined in Section 2 of the Program's Protocol and indicated in Schedule 1 to the Program's Protocol). See the illustrative diagram of the Reporting Period attached as Schedule 7 to the Program's Protocol. For each Patient, the Reporting Period depends on the date the Vaccine was administered to the Patient. To calculate the Reporting Period that applies to the Patient, the Patient (or a person who is a duly authorized to represent the Patient as provided in part (ii) of the definition of Applicant in the Program's Protocol) needs to:
   1. determine (through Schedule 1 to the Program's Protocol) what is the date of the Scope of Coverage End Point that applies to the Vaccine that was administered to Patient; and
   2. calculate the number of months and days from the vaccination date (i.e. date that the Vaccine was administered to the Patient) until the date of the Vaccine’s Scope of Coverage End Point, and add another 36 months. This establishes the Reporting Period that applies to the Patient.